ABBVIE INC (ABBV)       146.28  -1.12 (-0.76%)

146.28  -1.12 (-0.76%)

US00287Y1091 - Common Stock - Premarket: 146 -0.28 (-0.19%)

ABBVIE INC146.28

NYSE:ABBV (1/27/2023, 7:04:00 PM)-1.12 (-0.76%)

Premarket: 146 -0.28 (-0.19%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 10-28 2022-10-28/bmo Earnings (Next) 01-31 2023-01-31
Ins Owners 0.1% Inst Owners 69.2%
Market Cap 258.69B Shares 1.77B
PE 10.77 Fwd PE 12.32
Dividend Yield 3.85% Analysts 75.15
IPO 01-02 2013-01-02

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ABBV Daily chart

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. The company also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Company Info

ABBVIE INC

1 N Waukegan Rd

North Chicago ILLINOIS 60064

P: 18479327900.0

CEO: Richard A. Gonzalez

Employees: 50000

Website: https://www.abbvie.com/

ABBV News

News Image20 hours ago - Seeking AlphaAbbVie’s global bestseller Humira to face knockoffs this week (NYSE:ABBV)

After adding $208B in sales over two decades, AbbVie's (ABBV) monopoly over world's best selling drug Humira (adalimumab) is about to end as copycats enter. Read the full story here.

News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now or You’ll Be Kicking Yourself Later

Dividend stocks are a hedge against volatile markets. Here are seven dividend stocks that you should buy now before you regret missing out.

News Image2 days ago - The Motley Fool2 of the Best Dividend Stocks to Own in 2023

You can count on them for passive income and growth over time.

News Image3 days ago - Seeking AlphaJ&J pulls Imbruvica combo filing in EU as EMA cites potential 'serious side effects'

A committee of the European Medicines Agency ((EMA)) said that Johnson & Johnson (JNJ) withdrew its application seeking expanded approval of blood cancer drug Imbruvica on Dec

News Image4 days ago - Market News VideoInteresting ABBV Put And Call Options For March 10thNews Image5 days ago - InvestorPlace3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

ABBV Twits

Here you can normally see the latest stock twits on ABBV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example